Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rank in Stocks #99999
Acticor Biotech SAS operates as a clinical stage biotechnology company that... Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
Share Price
$0.28545656
Market Cap
$4.50M
Change (1 day)
5.97%
Change (1 year)
0.00%
Country
FR
Trade Acticor Biotech SAS (ALACT)

Category

P/S ratio for Acticor Biotech SAS (ALACT)
P/S ratio as of March 2026 TTM: 0.00
According to Acticor Biotech SAS latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2022 the company had a P/S ratio of 0.00.
P/S ratio history for Acticor Biotech SAS from 2010 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 -100.00%
2018 432.73 16,252.85%
2017 2.65 56.77%
2016 1.69 23.03%
2015 1.37 16.08%
2014 1.18 -11.28%
2013 1.33 -13.75%
2012 1.54 -29.62%
2011 2.19 -58.15%
2010 5.24 0.00%
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
3.55 -
DK
9.90 -
US
5.40 -
US
6.14 -
BE
3.04 -
AU